Eric Sullivan
Director/Board Member at CHIMERIC THERAPEUTICS LIMITED
Net worth: - $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Phillip Hains | M | 64 | 1 years | |
Lesley Russell | M | 63 | 4 years | |
Philip Kantoff | M | 69 |
Convergent Therapeutics, Inc.
Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company located in Cambridge, MA. The company focuses on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, a professor of urologic oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. The company's lead product candidate, Conv01-?, is a monoclonal antibody conjugated with actinium-225 (225Ac), a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA). If FDA-approved, Conv01-? would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment. The company was founded by Philip Wayne Kantoff and Neil H. Bander, and Philip Wayne Kantoff has been the CEO since incorporation. | - |
Neil Bander | M | - |
Convergent Therapeutics, Inc.
Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company located in Cambridge, MA. The company focuses on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, a professor of urologic oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. The company's lead product candidate, Conv01-?, is a monoclonal antibody conjugated with actinium-225 (225Ac), a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA). If FDA-approved, Conv01-? would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment. The company was founded by Philip Wayne Kantoff and Neil H. Bander, and Philip Wayne Kantoff has been the CEO since incorporation. | - |
John Agwunobi | M | 59 | 7 years | |
Paul Hopper | M | 68 | 4 years | |
Jason B. Litten | M | 50 | 2 years | |
Alexander Brown | M | - |
Convergent Therapeutics, Inc.
Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company located in Cambridge, MA. The company focuses on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, a professor of urologic oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. The company's lead product candidate, Conv01-?, is a monoclonal antibody conjugated with actinium-225 (225Ac), a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA). If FDA-approved, Conv01-? would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment. The company was founded by Philip Wayne Kantoff and Neil H. Bander, and Philip Wayne Kantoff has been the CEO since incorporation. | 3 years |
Elizabeth Chang | F | - | - | |
Li Ren | M | - | 3 years | |
Elizabeth Pingpank | F | - | 8 years | |
Eliot Bourk | M | - | 3 years | |
Nathan Jong | M | - | - | |
Alison Gartner | F | - | - | |
Kelly R. Thornburg | M | 60 | 2 years | |
Stephanie H. Astrow | M | 63 | 2 years | |
Cassandra Harrison | F | - | 2 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jennifer Chow | F | - | 4 years | |
Joanne Smith-Farrell | M | 54 | - | |
Douglas A. Melton | M | 70 | 3 years | |
James M. DeTore | M | 59 | 2 years | |
Cynthia Elkins | F | 58 | 2 years | |
Susanna High | F | 56 | 3 years | |
Mark Angelino | M | 51 | 4 years | |
Robert Ross | M | 50 | 4 years | |
Derek Adams | M | 50 | 4 years | |
Mohammed Asmal | M | - | 3 years | |
Sachiyo Minegishi | F | 46 | 4 years | |
Andrew Scharenberg | M | - | 3 years | |
Susan Abu-Absi | M | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 16 | 53.33% |
Australia | 14 | 46.67% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Eric Sullivan
- Personal Network